Cancer affects families across every region, but its burden is not distributed evenly by cancer type, geography, sex, age, or access to care. In 2022, an estimated 20 million people developed cancer worldwide and 9.7 million died from it. The same year, about 53.5 million people were living within five years of a cancer diagnosis. These figures, reported in the IARC global cancer burden 2022 analysis, show why reliable statistics matter to patients, caregivers, and support networks.
Contents
- Global cancer burden
- Prevention and avoidable risk
- The most common cancers worldwide
- Breast and cervical cancer differences
- Cancer statistics in the United States
- U.S. breast and lung cancer estimates
Global cancer burden
The IARC global cancer burden 2022 analysis estimates that about 1 in 5 people develop cancer during their lifetime. Mortality is also substantial: about 1 in 9 men die from cancer, compared with about 1 in 12 women. These are population-level estimates, not predictions for an individual person, and they describe worldwide patterns rather than the experience of a particular country or family.
The number of people living after a diagnosis is an important complement to incidence and mortality. An estimated 53.5 million people were alive within five years following a cancer diagnosis worldwide in 2022, according to the IARC global cancer burden 2022 analysis. For caregivers, this survivorship figure reflects the scale of ongoing needs that may extend beyond initial treatment, including appointments, recovery support, monitoring, and practical help at home.
The global figures also underline why a single “cancer rate” cannot describe every caregiving situation. Cancer includes many diseases with different causes, treatment pathways, outcomes, and support requirements. Comparing incidence with mortality can help show where the largest burdens are concentrated, while survival statistics can illustrate how outcomes differ by cancer type and stage.
Prevention and avoidable risk
The IARC preventable causes analysis 2026 estimates that 37% of all new cancer cases in 2022—about 7.1 million cases—were linked to preventable causes. This estimate concerns population-level attribution. It does not mean that every individual case had a single identifiable cause or that prevention can eliminate cancer altogether.
Lung cancer provides a specific example of how prevention statistics can be interpreted. The WHO lung cancer fact sheet reports that more than 1.3 million lung cancer cases in men and nearly 500,000 cases in women were preventable. The majority of preventable lung cancer is attributable to tobacco smoking, which accounts for 60% to 70% of cases, according to the same source.
These numbers can be relevant to caregiver support because prevention, diagnosis, treatment, and recovery often involve different forms of family assistance. A caregiver may help with screening appointments, smoking cessation support, treatment logistics, or symptom monitoring. Statistics identify broad patterns; they do not assign responsibility to a patient or family.
The most common cancers worldwide
The leading cancer types account for large shares of global diagnoses and deaths. The following table brings together the worldwide 2022 estimates reported by the WHO cancer fact sheets and the IARC global cancer burden 2022 analysis.
| Cancer type | Estimated new cases worldwide, 2022 | Estimated deaths worldwide, 2022 | Share of global cases |
|---|---|---|---|
| Lung cancer | 2.5 million | 1.8 million | 12.4% |
| Female breast cancer | 2.3 million | 670,000 | 11.6% |
| Colorectal cancer | 1.9 million | More than 900,000 | 9.6% |
| Cervical cancer | 660,000 | About 350,000 | Not supplied |
Lung cancer had an estimated 2.5 million new cases worldwide in 2022 and an estimated 1.8 million deaths, according to the WHO lung cancer fact sheet. It represented 12.4% of all cancer cases globally, based on the IARC global cancer burden 2022 analysis. Around 85% of lung cancer cases are non-small cell lung cancer, according to WHO.
Female breast cancer had an estimated 2.3 million new cases worldwide in 2022 and caused an estimated 670,000 deaths, according to the WHO breast cancer fact sheet. The IARC global cancer burden 2022 analysis reports that female breast cancer represented 11.6% of all cancer cases globally.
Colorectal cancer had an estimated 1.9 million new cases worldwide in 2022 and caused more than 900,000 deaths, according to the WHO colorectal cancer fact sheet. The IARC global cancer burden 2022 analysis reports that colorectal cancer represented 9.6% of all global cancer cases. WHO also reports that colorectal cancer incidence rates in Europe are among the highest in the world, while mortality rates in Eastern Europe are among the highest in the world.
Breast and cervical cancer differences
Breast cancer risk and outcomes vary by human development level. In countries with a very high HDI, 1 in 12 women will be diagnosed with breast cancer during their lifetime, and 1 in 71 will die from breast cancer, according to the WHO breast cancer fact sheet. In countries with a low HDI, 1 in 27 women will be diagnosed with breast cancer during their lifetime, and 1 in 48 will die from it.
These paired statistics should be read together. A lower estimated lifetime diagnosis risk does not automatically mean a lower mortality burden. Differences in detection, diagnosis, treatment access, and other health-system conditions can affect how incidence and death estimates relate to one another. The figures describe country groups by HDI, not every country or person within those groups.
About 80% of breast cancers develop in women with no modifiable breast cancer risk factor other than sex and age, according to WHO. Approximately 0.5% to 1% of breast cancers occur in men. Caregivers therefore support people with breast cancer across a range of backgrounds and circumstances; the presence or absence of a modifiable risk factor does not determine whether a person needs care.
Cervical cancer had an estimated 660,000 new cases globally in 2022 and caused about 350,000 deaths, according to the WHO cervical cancer fact sheet. About 94% of cervical cancer deaths occurred in low- and middle-income countries in 2022. WHO also reports that women living with HIV are six times more likely to develop cervical cancer than women in the general population, and that an estimated 5% of all cervical cancer cases are attributable to HIV.
Cancer statistics in the United States
U.S. figures use different definitions, years, and statistical systems, so they should not be combined directly with worldwide estimates. CDC U.S. Cancer Statistics technical notes report 1,851,238 invasive cancer diagnoses in the United States in 2022. In 2023, 613,349 people living in the United States died from cancer, according to the same CDC source.
The scale of U.S. data collection is also substantial. The NCI Cancer Statistics page states that the SEER Program covers approximately 48% of the U.S. population. The CDC U.S. Cancer Statistics public use page reports that its public use database contains more than 39 million cancer cases since 2001.
SEER identifies several cancers as especially important in the U.S. distribution. Breast, lung and bronchus, prostate, and colorectal cancers account for almost 50% of all new cancer cases in the United States, according to SEER Common Cancer Sites. Lung and bronchus, colorectal, pancreatic, and breast cancers are responsible for nearly 50% of all cancer deaths in the United States, according to the same SEER source.
For caregivers, these groupings show why support needs can vary widely even within a single national total. A diagnosis may involve surgery, radiation, systemic treatment, long-term surveillance, or care focused on advanced disease. The statistics identify the cancers contributing most to national totals; they do not specify an individual treatment plan.
U.S. breast and lung cancer estimates
SEER’s 2026 estimates provide a more detailed comparison of two major U.S. cancer categories. These are estimates for 2026, not counts already observed in that year.
| U.S. cancer category | Estimated new cases, 2026 | Estimated deaths, 2026 | Other reported measure |
|---|---|---|---|
| Female breast cancer | 321,910 | 42,140 | 91.9% five-year relative survival |
| Lung and bronchus cancer | 229,410 | 124,990 | 47.2 cases per 100,000 people per year |
Female breast cancer represents 15.2% of all new cancer cases in the United States, according to SEER Female Breast Cancer. Its U.S. incidence rate is 132.5 per 100,000 women per year, and it is most frequently diagnosed among women aged 65 to 74. SEER reports a 91.9% five-year relative survival rate for female breast cancer. The 2026 estimates are 321,910 new cases and 42,140 deaths.
For lung and bronchus cancer, SEER estimates 229,410 new U.S. cases and 124,990 U.S. deaths in 2026. Lung and bronchus cancer represents 10.8% of all new cancer cases in the United States, and its incidence rate is 47.2 per 100,000 people per year, according to SEER Lung and Bronchus Cancer.
Stage is a major distinction in the lung cancer survival figures supplied by SEER. Localized lung and bronchus cancer has a five-year relative survival rate of 65.5%, while distant-stage lung and bronchus cancer has a rate of 10.5%. These are relative survival measures for population groups, not a forecast of what will happen to a specific patient. They also show why the same cancer name can correspond to very different caregiving needs.
Taken together, the worldwide and U.S. statistics describe a large and varied population: people newly diagnosed, people receiving treatment, people living after diagnosis, and families supporting someone through each phase. Measurement year, geography, cancer type, stage, and whether a figure is an estimate or an observed count all matter when interpreting cancer statistics.